<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743678</url>
  </required_header>
  <id_info>
    <org_study_id>2008-04-018</org_study_id>
    <nct_id>NCT00743678</nct_id>
  </id_info>
  <brief_title>Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis</brief_title>
  <official_title>A Phase II Study of Neoadjuvant FOLFOX6 Plus Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An innovative therapeutic strategy to increase the complete resection rate is of utmost&#xD;
      importance in order to enhance survival in colorectal cancer patients with unresectable&#xD;
      liver-only metastasis. Therefore, the investigators propose a prospective study of&#xD;
      neoadjuvant chemotherapy using FOLFOX6 plus cetuximab to convert initially unresectable liver&#xD;
      metastasis to potentially resectable disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will include the patients with unresectable liver-only metastatic disease independent of&#xD;
      EGFR status. The results of this study will show the resection rate with neoadjuvant&#xD;
      treatment in patients with colorectal cancer with liver-only metastasis.&#xD;
&#xD;
      Restaging including CT after #3, #6, #9, and #12 cycles of FOLFOX + Cetuximab&#xD;
&#xD;
      If any time, patients have PD, Off-study SD, Continue study treatment until resectable, up to&#xD;
      #12 cycles, PD, or toxicities PR or more, If resectable, go to surgery : resection of liver&#xD;
      metastasis and primary tumor, if present If unresectable, continue until resectable, up to&#xD;
      #12 cycles, PD, or toxicities&#xD;
&#xD;
      Overall, a total of 12 cycles of treatment including neoadjuvant therapy will be given either&#xD;
      before, after or without surgery.&#xD;
&#xD;
      CT scans will be performed every 3 cycles during the first 12 cycles (6 months). After that,&#xD;
      CT scans will be performed every 2 months for another 6 months, then every 3 months for 6&#xD;
      months, then once a year or earlier if a PD is probable.&#xD;
&#xD;
      AEs will be evaluated once every cycle and during the CT evaluation visit.. Patients that can&#xD;
      only undergo R1 resection or are unable to get surgery at all, will be evaluated regularly&#xD;
      until PD.&#xD;
&#xD;
      Radiofrequency ablation (RFA) may be allowed as a palliative local therapy in patients that&#xD;
      are suitable for it. RFA is not considered equal to a resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate overall R0 resection rates following neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (according to RECIST)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival timeToxicity profile (according to NCI CTCAE v3)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative analyses between pretreatment EGFR, KRAS mutation and response rate/survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Unresectable Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>NEO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6/cetuximab</intervention_name>
    <description>Neoadjuvant FOLFOX6/cetuximab</description>
    <arm_group_label>NEO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven colorectal cancer with metastatic lesion(s) in the liver that is&#xD;
             (are) unresectable&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  ECOG performance 0 - 1&#xD;
&#xD;
          -  Adequate organ function ((hepatic transaminases ≤ 5x upper limit of normal, bilirubin&#xD;
             &lt; 2.0 x upper limit of normal, and creatinine ≤ 1.5x upper limit of normal, platelet &gt;&#xD;
             100,000/ul, absolute neutrophil count ≥ 1,500/ul)&#xD;
&#xD;
          -  At least one measurable lesion by RECIST criteria&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resectable liver metastasis&#xD;
&#xD;
          -  Extrahepatic metastases, regardless of their resectability&#xD;
&#xD;
          -  Chronic active hepatitis or cirrhosis&#xD;
&#xD;
          -  Prior therapy for metastatic disease&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Uncontrolled medical illnesses including medically uncontrolled infection,&#xD;
             uncontrolled hypertension, unstable angina, symptomatic congestive heart failure,&#xD;
             myocardial infarction within 6 months&#xD;
&#xD;
          -  Previous adjuvant FOLFOX chemotherapy&#xD;
&#xD;
          -  Prior adjuvant chemotherapy, if administered within 6 months before study entry&#xD;
&#xD;
          -  Known hypersensitivity reaction to any of the components of study treatment&#xD;
&#xD;
          -  Prior agents directed against EGFR&#xD;
&#xD;
          -  Prior allergic reaction (known sensitivity) to chimerized or murine monoclonal&#xD;
             antibody therapy&#xD;
&#xD;
          -  Known alcohol or drug abuse&#xD;
&#xD;
          -  Participation in another clinical study within the 30 days before registration&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Other previous malignancy with exception of a history of a previous curatively treated&#xD;
             basal cell carcinoma of the skin of pre-invasive carcinoma of the cervix.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Suk Park, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Young Suk Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Unresectable liver metastasis</keyword>
  <keyword>FOLFOX6</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Neoadjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

